RBC Capital raises Aptiv target to $90, maintains Outperform
RBC Capital analyst Tom Narayan maintained an Outperform rating on Aptiv and raised the price target to $90 from $81. JP Morgan maintained an Overweight rating but lowered its target to $75, while Deutsche Bank kept a Buy rating with a target of $75.

*this image is generated using AI for illustrative purposes only.
RBC Capital analyst Tom Narayan has maintained an Outperform rating on Aptiv (NYSE: APTV) while raising the price target to $90 from $81. This adjustment signals increased confidence in the stock's potential to outperform the broader market. The revised target reflects a positive reassessment of the company's future performance and valuation.
Rating and Price Target Changes
The updated price target from RBC Capital contrasts with recent adjustments by other firms. While RBC Capital has raised its outlook, JP Morgan analyst Ryan Brinkman maintained an Overweight rating but lowered the price target to $75 from $84. Deutsche Bank analyst Edison Yu previously maintained a Buy rating, increasing the price target to $75 from $74.
| Firm | Analyst | Rating | Previous Price Target | New Price Target |
|---|---|---|---|---|
| RBC Capital | Tom Narayan | Outperform | $81 | $90 |
| JP Morgan | Ryan Brinkman | Overweight | $84 | $75 |
| Deutsche Bank | Edison Yu | Buy | $74 | $75 |
The divergence in price targets among analysts highlights varying perspectives on Aptiv's market position. Despite the lower target from JP Morgan, the Overweight rating suggests an expectation of outperformance relative to the market. RBC Capital's increase to $90 places it at the top of the current range, indicating a more bullish stance on the stock's trajectory.
What specific factors are driving RBC Capital's increased confidence in Aptiv's future performance?
How might the divergence in analyst price targets impact investor sentiment towards Aptiv?
What upcoming catalysts could further influence Aptiv's stock trajectory in the near term?


























